# Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)

> **NCT00681031** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 96 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** ZOSTAVAX®

## Key facts

- **NCT ID:** NCT00681031
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-14
- **Primary completion:** 2008-06-25
- **Final completion:** 2008-06-25
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681031, "Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00681031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*